

2. Scale-up production of fusion proteins constructed by NCI if required.

3. Conduct in vitro studies to identify putative antagonists/agonists by screening libraries of compounds.

4. Conduct in vitro and in vivo studies to characterize the properties of putative antagonists/agonists.

5. Conduct clinical studies of best candidates.

For ligand-mediated histochemical experiments:

1. Test conditioned medium for suitability in histochemical experiments.

2. Screen tumor samples or biopsies for reactivity.

3. Conduct clinical studies of diagnostic test.

Criteria for choosing the company include its demonstrated experience and commitment to the following:

1. Scientific expertise in and demonstrated commitment to the treatment of neoplasia, arteriosclerosis, fibrotic diseases and related disorders.

2. Scientific expertise in and demonstrated commitment to the development of drug delivery systems.

3. Experience in preclinical and clinical drug development.

4. Experience and ability to produce, package, market and distribute pharmaceutical products.

5. Experience in the monitoring, evaluation and interpretation of the data from investigational agent clinical studies under an IND.

6. A willingness to cooperate with the NCI in the collection, evaluation, publication and maintaining of data from pre-clinical studies and clinical trials regarding the subject compounds.

7. Provide defined financial and personnel support for the CRADA to be mutually agreed upon.

8. An agreement to be bound by the DHHS rules involving human and animal subjects.

9. The aggressiveness of the development plan, including the appropriateness of milestones and deadlines for preclinical and clinical development.

10. Provisions for equitable distribution of patent rights to any CRADA inventions. Generally the rights of ownership are retained by the organization which is the employer of the inventor, with (1) an irrevocable, nonexclusive, royalty-free license to the Government and (2) an option for the collaborator to elect an exclusive or nonexclusive license to Government owned rights under terms that comply with the appropriate licensing statutes and regulations.

Dated: November 4, 1996.

Thomas D. Mays,

Director, Office of Technology Development,  
OD, NCI.

[FR Doc. 96-29346 Filed 11-14-96; 8:45 am]

BILLING CODE 4140-010-M

### **National Heart, Lung, and Blood Institute; Division of Lung Diseases, Phase II or Phase III Clinical Trials**

The National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome Network, a group of 10 academic medical centers consisting of 24 hospitals with expertise in clinical research relating to acute adult lung injury, invites letters of interest by December 1, 1996 from private sector companies who have developed novel therapies for acute lung injury and/or acute respiratory distress syndrome (ARDS) and who are interested in collaborating in Phase II or Phase III clinical trials. Letters of interest will not be viewed as a formal commitment, but are invited as a first step in exploring possible future collaborations. Information submitted will be treated as strictly confidential. Letters of interest should include a proposal regarding the nature of possible interactions with the ARDS Network. Network investigators and NHLBI staff will select agents for study based on scientific interests, novelty, feasibility, and availability. It is anticipated that clinical trials of agents selected will be initiated as early as 1997, but later starting dates will also be considered. Letters should be sent by December 1, 1996 to Dorothy Berlin Gail, Ph.D., Director, Lung Biology and Disease Program, Division of Lung Diseases, NHLBI, 6701 Rockledge Drive Room 10100, Bethesda, Maryland 20892-7952.

Dated: November 7, 1996.

Sheila E. Merritt,

Executive Officer, NHLBI.

[FR Doc. 96-29345 Filed 11-14-96; 8:45 am]

BILLING CODE 4140-01-M

### **National Institute on Deafness and Other Communication Disorders; Notice of Closed Meeting**

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 United States Code Appendix 2), notice is hereby given of the following meeting:

*Name of Committee:* National Institute on Deafness and Other Communication Disorders Special Emphasis Panel.

*Date:* December 3-5, 1996.

*Time:* 8 am-5 pm, December 3, 8 am-5 pm, December 4, 8 am to adjournment, December 5.

*Place:* Doubletree Hotel, 1750 Rockville Pike, Rockville MD 20852.

*Contact Person:* Mary V. Nekola, Ph.D., Scientific Review Administrator, NIDCD/DEA/SRB, EPS Room 400C, 6120 Executive Boulevard, MSC 7180, Bethesda MD 20892-7180, 301-496-8683.

*Purpose/Agenda:* To review and evaluate program project applications. The meeting will be closed in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6) Title 5, United States Code. The applications and/or proposals and the discussion could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications and/or proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

This notice is being published less than fifteen days prior to the meeting due to the urgent need to meet timing limitations imposed by the review and funding cycle.

(Catalog of Federal Domestic Assistance Program No. 93.173 Biological Research Related to Deafness and Communication Disorders)

Dated: November 6, 1996.

Paula N. Hayes,

Acting Committee Management Officer, NIH.

[FR Doc. 96-29250 Filed 11-14-96; 8:45 am]

BILLING CODE 4140-01-M

### **National Institute on Deafness and Other Communication Disorders; Notice of Closed Meeting**

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 United States Code Appendix 2), notice is hereby given of the following meeting:

*Name of Committee:* National Institute on Deafness and Other Communication Disorders Special Emphasis Panel.

*Date:* November 26, 1996.

*Time:* 3 pm to adjournment.

*Place:* 6120 Executive Blvd., Room 400C, Rockville, Maryland (telephone conference call).

*Contact Person:* Craig A. Jordan, Ph.D., Scientific Review Administrator, NIDCD/DEA/SRB, EPS Room 400C, 6120 Executive Boulevard, MSC 7180, Bethesda, MD 20892-7180, 301-496-8683.

*Purpose/Agenda:* To review and evaluate contract proposals.

The meeting will be closed in accordance with the provisions set forth in sections 552(c)(4) and 552(c)(6) Title 5, United States Code. The applications and/or proposals and the discussion could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications and/or proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.